+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Market Spotlight: NHL: Peripheral T-cell lymphoma (PTCL)

  • ID: 4533505
  • Report
  • May 2021
  • Region: Global
  • 39 Pages
  • Pharma Intelligence
This Market Spotlight report covers the Peripheral T-Cell Lymphoma (PTCL) market, comprising key marketed and pipeline drugs, clinical trials, upcoming events, recent events and analyst opinion, probability of success, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways
  • The publisher estimates that in 2017, there were approximately 19,950 incident cases of peripheral T-cell lymphoma (PTCL) worldwide, and forecasts that number to increase to 23,880 incident cases by 2026.
  • It is estimated that the majority of diagnosed cases were in males in 2017.
  • The incidence of PTCL is highest among older individuals aged 60+ years. The approved drugs in the PTCL space focus on a wide variety of targets. These drugs are administered via the intravenous and oral routes.
  • The majority of industry-sponsored drugs in active clinical development for PTCL are in Phase II. Therapies in development for PTCL focus on a wide variety of targets. These therapies are administered via the oral and intravenous routes.
  • High-impact upcoming events for drugs in the PTCL space comprise topline Phase II trial results for IPH4102 and an expected supplemental CHMP opinion for Adcetris.
  • The overall likelihood of approval of a Phase I hematologic asset is 8.6%, and the average probability a drug advances from Phase III is 59.1%. Drugs, on average, take 9.5 years from Phase I to approval, compared to 9.6 years in the overall oncology space.
  • The distribution of clinical trials across Phase I–IV indicates that the vast majority of trials for PTCL have been in the early and mid-phases of development, with 93% of trials in Phase I–II, and only 7% in Phase III–IV.
  • The US has a substantial lead in the number of PTCL clinical trials globally. France and the UK lead the major European markets, while China has the top spot in Asia.
  • Clinical trial activity in the PTCL space is dominated by completed trials. Bristol Myers Squibb has the highest number of completed clinical trials for PTCL, with 11 trials.
  • Bristol Myers Squibb leads industry sponsors with the highest overall number of clinical trials for PTCL, followed by Seagen and Takeda.
Note: Product cover images may vary from those shown

OVERVIEWKEY TAKEAWAYS
DISEASE BACKGROUND
  • Subtypes

TREATMENTEPIDEMIOLOGYMARKETED DRUGSPIPELINE DRUGS
RECENT EVENTS AND ANALYST OPINION
  • ALXN2075 for PTCL (December 8, 2019)
  • Tipifarnib (Oncology) for PTCL (December 8, 2019)
  • Copiktra for PTCL (December 7, 2019)

KEY UPCOMING EVENTSPROBABILITY OF SUCCESS
LICENSING AND ASSET ACQUISITION DEALS
  • Curon Picks Up China-Plus Rights to Rhizen’s Tenalisib

REVENUE OPPORTUNITY
CLINICAL TRIAL LANDSCAPE
  • Sponsors by status
  • Sponsors by phase

BIBLIOGRAPHYAPPENDIX
LIST OF FIGURES
Figure 1: Trends in incident cases of PTCL, 2017–26
Figure 2: Incident cases of PTCL, by age, 2017
Figure 3: Overview of pipeline drugs for PTCL in the US
Figure 4: Pipeline drugs for PTCL, by company
Figure 5: Pipeline drugs for PTCL, by drug type
Figure 6: Pipeline drugs for PTCL, by classification
Figure 7: ALXN2075 for PTCL (December 8, 2019): Phase I/IIa - Two Part Dose Escalation
Figure 8: Key upcoming events in PTCL
Figure 9: Probability of success in the hematologic pipeline
Figure 10: Clinical trials in PTCL
Figure 11: Top 10 drugs for clinical trials in PTCL
Figure 12: Top 10 companies for clinical trials in PTCL
Figure 13: Trial locations in PTCL
Figure 14: PTCL trials status
Figure 15: PTCL trials sponsors, by phase
LIST OF TABLES
Table 1: Incident cases of PTCL, 2017–26
Table 2: Incident cases of PTCL, by gender, 2017
Table 3: Marketed drugs for PTCL
Table 4: Pipeline drugs for PTCL in the US
Table 5: ALXN2075 for PTCL (December 8, 2019)
Table 6: Tipifarnib (Oncology) for PTCL (December 8, 2019)
Table 7: Copiktra for PTCL (December 7, 2019)
Table 8: Historical global sales, by drug ($m), 2016–20
Table 9: Forecasted global sales, by drug ($m), 2021–25
Note: Product cover images may vary from those shown